The device, which was developed in collaboration with a specialist in synthetic bone substitutes, will enhance bone growth and enable safer vertebral fusion.

Safe Orthopaedics’ scientific advisory board member Dr Antonio Faundez said: “This bone substitute is an ideal fit for the Walnut cage.

“It dovetails perfectly with Safe Orthopaedics’ strategy of offering effective solutions, while providing the surgeon with flexibility in how to use it.”

Safe Orthopaedics CEO Pierre Dumouchel said: “This bone substitute will help us to meet growing demand from surgeons, and we are delighted to be able to offer it in conjunction with our Walnut cervical cage.”

The company has also secured 510(k) clearance from the US Food and Drug Administration (FDA) for its SteriSpineCC range (Walnut cage and associated single-use ancillary).

In addition, the firm is planning to get marketing approval for the SteriSpineCC range in certain countries such as Latin America and the Asia-Pacific region.

Established in 2010, the company is engaged in the development of sterile implants and associated single-use instruments.

The firm’s products will be used to reduce risk of contamination and infection, as well as facilitate minimally-invasive approach for trauma and degenerative pathologies.

With 17 patent families, the SteriSpine kits are CE-marked and FDA approved.